Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.12
(0.8%)
CNY 10.12
(0.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 772.59 Million CNY | -27.4% |
| 2022 | 1.06 Billion CNY | -11.49% |
| 2021 | 1.2 Billion CNY | -23.27% |
| 2020 | 1.56 Billion CNY | -33.38% |
| 2019 | 2.35 Billion CNY | 1.09% |
| 2018 | 2.32 Billion CNY | 16.84% |
| 2017 | 1.99 Billion CNY | 25.27% |
| 2016 | 1.58 Billion CNY | 897.74% |
| 2015 | 159.35 Million CNY | -22.69% |
| 2014 | 206.11 Million CNY | 26.77% |
| 2013 | 162.59 Million CNY | 26.38% |
| 2012 | 128.65 Million CNY | 88.31% |
| 2011 | 68.32 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 654.08 Million CNY | -15.34% |
| 2024 Q3 | 682.79 Million CNY | 0.47% |
| 2024 Q2 | 679.56 Million CNY | 3.9% |
| 2023 Q3 | 883.77 Million CNY | -1.04% |
| 2023 FY | 772.59 Million CNY | -27.4% |
| 2023 Q1 | 902.65 Million CNY | -15.18% |
| 2023 Q2 | 893.02 Million CNY | -1.07% |
| 2023 Q4 | 772.59 Million CNY | -12.58% |
| 2022 Q4 | 1.06 Billion CNY | -5.36% |
| 2022 FY | 1.06 Billion CNY | -11.49% |
| 2022 Q2 | 1.16 Billion CNY | 4.8% |
| 2022 Q1 | 1.1 Billion CNY | -7.73% |
| 2022 Q3 | 1.12 Billion CNY | -3.29% |
| 2021 Q3 | 1.23 Billion CNY | -11.91% |
| 2021 Q2 | 1.4 Billion CNY | 1.37% |
| 2021 Q1 | 1.38 Billion CNY | -11.49% |
| 2021 FY | 1.2 Billion CNY | -23.27% |
| 2021 Q4 | 1.2 Billion CNY | -2.94% |
| 2020 FY | 1.56 Billion CNY | -33.38% |
| 2020 Q4 | 1.56 Billion CNY | -7.27% |
| 2020 Q3 | 1.69 Billion CNY | -12.82% |
| 2020 Q2 | 1.93 Billion CNY | -3.49% |
| 2020 Q1 | 2 Billion CNY | -14.61% |
| 2019 Q2 | 2.52 Billion CNY | 7.06% |
| 2019 Q1 | 2.35 Billion CNY | 1.37% |
| 2019 FY | 2.35 Billion CNY | 1.09% |
| 2019 Q4 | 2.35 Billion CNY | 0.44% |
| 2019 Q3 | 2.34 Billion CNY | -7.26% |
| 2018 Q2 | 2.36 Billion CNY | 61.65% |
| 2018 Q1 | 1.46 Billion CNY | -26.6% |
| 2018 FY | 2.32 Billion CNY | 16.84% |
| 2018 Q4 | 2.32 Billion CNY | 5.27% |
| 2018 Q3 | 2.21 Billion CNY | -6.45% |
| 2017 FY | 1.99 Billion CNY | 25.27% |
| 2017 Q1 | 1.02 Billion CNY | -35.35% |
| 2017 Q4 | 1.99 Billion CNY | 67.58% |
| 2017 Q3 | 1.18 Billion CNY | 9.89% |
| 2017 Q2 | 1.08 Billion CNY | 5.23% |
| 2016 Q2 | 563.94 Million CNY | 60.02% |
| 2016 Q4 | 1.58 Billion CNY | 141.61% |
| 2016 Q3 | 658.06 Million CNY | 16.69% |
| 2016 Q1 | 352.42 Million CNY | 121.15% |
| 2016 FY | 1.58 Billion CNY | 897.74% |
| 2015 Q2 | 140.88 Million CNY | -9.21% |
| 2015 Q3 | 153.28 Million CNY | 8.8% |
| 2015 Q1 | 155.17 Million CNY | -24.72% |
| 2015 FY | 159.35 Million CNY | -22.69% |
| 2015 Q4 | 159.35 Million CNY | 3.96% |
| 2014 Q4 | 206.11 Million CNY | -3.09% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 206.11 Million CNY | 26.77% |
| 2014 Q3 | 212.68 Million CNY | 0.0% |
| 2013 FY | 162.59 Million CNY | 26.38% |
| 2012 FY | 128.65 Million CNY | 88.31% |
| 2011 FY | 68.32 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 90.372% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 85.226% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | 38.81% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 46.871% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 48.76% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | 33.23% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -25.577% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 78.592% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -249.521% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | 23.254% |